Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

• Published in: The New England journal of medicine Vol. 381; no. 1; pp. 36 - 46
• Main Authors: Fervenza, Fernando C, Appel, Gerald B, Barbour, Sean J, Rovin, Brad H, Lafayette, Richard A, Aslam, Nabeel, Jefferson, Jonathan A, Gipson, Patrick E, Rizk, Dana V, Sedor, John R, Simon, James F, McCarthy, Ellen T, Brenchley, Paul, Sethi, Sanjeev, Avila-Casado, Carmen, Beanlands, Heather, Lieske, John C, Philibert, David, Li, Tingting, Thomas, Lesley F, Green, Dolly F, Juncos, Luis A, Beara-Lasic, Lada, Blumenthal, Samuel S, Sussman, Amy N, Erickson, Stephen B, Hladunewich, Michelle, Canetta, Pietro A, Hebert, Lee A, Leung, Nelson, Radhakrishnan, Jay, Reich, Heather N, Parikh, Samir V, Gipson, Debbie S, Lee, Dominic K, da Costa, Bruno R, Jüni, Peter, Cattran, Daniel C
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 04.07.2019
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin; Autoantibodies; Biopsy; Body weight; Clinical trials; Creatinine; Cyclosporine - adverse effects; Cyclosporine - therapeutic use; Cyclosporins; Drug Administration Schedule; Drug therapy; Evidence-based medicine; Female; Glomerulonephritis, Membranous - drug therapy; Humans; Hypertension; Immunoglobulins; Immunologic Factors - therapeutic use; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Immunotherapy; Infusions, Intravenous; Intention to Treat Analysis; Intravenous administration; Kaplan-Meier Estimate; Kidney diseases; Lymphocytes B; Male; Membranous nephropathy; Middle Aged; Monoclonal antibodies; Nephropathy; Phospholipase A2; Proteinuria; Proteinuria - drug therapy; Quality of life; Remission; Remission Induction; Rituximab; Rituximab - adverse effects; Rituximab - therapeutic use; Treatment Failure; Young Adult; Canada
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1814427

In a randomized, controlled trial involving patients with membranous nephropathy, rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission for up to 24 months.